Analysts Remain Encouraged By Bellicum Pharma's Progress

Loading...
Loading...
Bellicum Pharmaceuticals IncBLCM
has managed to keep
sell-side analysts
encouraged with its last Friday's presentation at the
European Hematology Association
meeting. The latest sell-side firm to express its happiness over the data was Raymond James.

Analyst Reni Benjamin termed the update on the company's ongoing phase 1/2 study of BPX-501 at the EHA as incrementally positive. The analyst said he continues to be encouraged that the treatment benefits were largely maintained, as more patients were treated and followed for a longer time.

Related News: Gates Foundation Deal Opens Things Up For OraSure Attention To Details: Neos' ADHD Portfolio

"More importantly, the results achieved by BPX-501 appear to be better than those seen with some other transplant approaches in historical studies," the analyst added.

Raymond James said it continues to recommend shares of Bellicum to long-term oriented, risk-tolerant investors on the following premises:

  • Continued progress made with the BPX-501 program both in the U.S. and EU.
  • The advancement of the CAR T/TCR franchise through clinical development.
  • Proforma net cash position of $145 million.

As such, Raymond James maintains its Outperform rating on the shares of Bellicum.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLong IdeasReiterationAnalyst RatingsTrading IdeasGeneralEHAEuropean Hematology AssociationRaymond JamesReni Benjamin
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...